Recent studies have focused on interleukin-13 (IL-13) and its receptor interleukin-13 receptor α2 (IL-13Rα2) in malignant tumor progression across various cancers, including melanoma, renal cell carcinoma, adrenocortical carcinoma, and brain tumors10–13. This evidence concerns the gene IL13 and renal cell carcinoma.